Wu Ying, Xiao Min, Zhu Li, Zhou Xiao-Xi, Gong Quan, Xin Xing, Li Chun-Rui, Zhou Jian-Feng, Deng Jin-Niu
Department of Hematology, Tongi Medical College Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Jun;19(3):585-8.
This study was aimed to investigate the expression of CD96 on bone marrow mononuclear cells (BMMNC) from 91 patients with acute leukemia, and the results were analyzed with clinical pathological data. Flow cytometry was used to detect CD96 molecule on the bone marrow mononuclear cell surface of 91 newly diagnosed patients with acute leukemia, and 15 healthy adults were served as normal controls. The results showed that the average rate of CD96(+) expression on BMMNC (CD45(+) CD34(+) CD19(+)) of 21 patients with B-ALL was (17.41 ± 27.97)%, the average rate of CD96(+) expression on stem cells (CD45(+)CD34(+)CD7(+)) of 11 patients with T-ALL was (46.98 ± 45.55)%, the average rate of CD96(+) expression on BMMNC (CD45(+)CD34(+)CD38(-)) of 59 patients with AML was (16.69 ± 25.08)%, while the average rate of CD96(+) on BMMNC of healthy adult controls was (0.52 ± 1.84)%, there was significant difference in average rate of CD96(+) expression between above-mentioned patients and healthy adult controls (p < 0.05). Otherwise the average rate of CD96(+) on BMMNC after treatment showed no statistical difference between patient group with CR (1.68 ± 2.31) and healthy controls, but demonstrated statistical difference between patients without CR and healthy controls (p > 0.05). The leukocyte count, hemoglobin level and platelet count in CD96(+) group had no obvious difference from CD96(-) ones (p > 0.05). No change found in the field of molecular biology and cytogenetic between these 2 groups. It is concluded that CD96 expression is different in different types of leukemia. The positive expression of CD96 on bone marrow hematopoietic stem cells in patients with acute leukemia may be associated with primary drug resistance, relapse and progression. The CD96 on BMMNC of acute leukemias can be a helpful prognostic indicator in treatment response assessment.
本研究旨在探讨91例急性白血病患者骨髓单个核细胞（BMMNC）上CD96的表达情况，并结合临床病理资料进行分析。采用流式细胞术检测91例初诊急性白血病患者骨髓单个核细胞表面的CD96分子，选取15名健康成年人作为正常对照。结果显示，21例B-ALL患者BMMNC（CD45(+)CD34(+)CD19(+)）上CD96(+)的平均表达率为（17.41±27.97）%，11例T-ALL患者干细胞（CD45(+)CD34(+)CD7(+)）上CD96(+)的平均表达率为（46.98±45.55）%，59例AML患者BMMNC（CD45(+)CD34(+)CD38(-)）上CD96(+)的平均表达率为（16.69±25.08）%，而健康成人对照组BMMNC上CD96(+)的平均表达率为（0.52±1.84）%，上述患者与健康成人对照组CD96(+)的平均表达率差异有统计学意义（p<0.05）。此外，治疗后患者组BMMNC上CD96(+)的平均表达率在CR患者（1.68±2.31）与健康对照组之间无统计学差异，但在未达CR的患者与健康对照组之间有统计学差异（p>0.05）。CD96(+)组的白细胞计数、血红蛋白水平和血小板计数与CD96(-)组无明显差异（p>0.05）。两组在分子生物学和细胞遗传学方面未发现变化。结论：不同类型白血病中CD96表达存在差异。急性白血病患者骨髓造血干细胞上CD96的阳性表达可能与原发耐药、复发及进展有关。急性白血病BMMNC上的CD96可作为治疗反应评估中一个有用的预后指标。
